…
INO earnings call for the period ending June 30, 2024.…
…
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
…
Both biotechs have been struggling for a while, but there might be some hope for them.…
…
The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal…
…
…
Oppenheimer maintains price target on Inovio Pharmaceuticals stock…
INO earnings call for the period ending March 31, 2024.…
…
…
Inovio Pharmaceuticals wird am 13.05.2024 das Zahlenwerk zum am 31.03.2024 abgelaufenen Jahresviertel vorstellen.In Sachen EPS gehen 5 Analysten von einem…
…
INO earnings call for the period ending December 31, 2023.…
…
The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…
…
Shares of Inovio Pharmaceuticals Inc. rose 8.29% to $0.44 Friday, on what proved to be an all-around mixed trading session…
INO earnings call for the period ending September 30, 2023.…
…
…
[235 + Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…
Leading dextromethorphan market players include AstraZeneca plc, FibroGen, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Merck…
INO earnings call for the period ending June 30, 2023....…
WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) revealed Loss for second quarter that decreased from last year and beat the…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
PLYMOUTH MEETING, Pa., Aug. 4, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
PLYMOUTH MEETING, Pa., July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Gainers
Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent…
WASHINGTON (dpa-AFX) - Inovio (INO) said that the European Commission granted orphan drug designation for INO-3107, the companys product candidate…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This…
INO earnings call for the period ending March 31, 2023....…
WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) reported Loss for first quarter that decreased from the same period last year…
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed…
PLYMOUTH MEETING, Pa., April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA…
WASHINGTON (dpa-AFX) - INOVIO (INO) announced that the European Committee for Orphan Medicinal Products has provided a positive opinion on…
WASHINGTON (dpa-AFX) - Inovio (INO) said that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine…
The biotech stock, still reeling from a failed clinical trial, hit a 52-week low....…